Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanuja Chitnis

Showing results (81-90 of 409) with videos related to

Pageof 41
Sort By:
Neurology|September 30, 2016
Physical activity and the incidence of multiple sclerosisKirsten S Dorans, Jennifer Massa, Tanuja Chitnis, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|February 6, 2023
Fronto-striatal damage may contribute to resistance to fatigue-lowering medications in multiple sclerosisMiklos Palotai, Diana Pintye, Bonnie Glanz, et al.
The Lancet. Neurology|September 27, 2025
Blood and CSF biomarkers for multiple sclerosis: emerging clinical applicationsTanuja Chitnis, Roberta Magliozzi, Ahmed Abdelhak, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2017
Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patientsNeda Sattarnezhad, Samantha Farrow, Dorlan Kimbrough, et al.
Nutritional Neuroscience|March 5, 2021
Triad of hypovitaminosis A, hyperostosis, and optic neuropathy in males with autism spectrum disordersDeena Godfrey, Robert T Stone, Marcus Lee, et al.
Scientific Reports|July 26, 2020
Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseasesShrishti Saxena, Hrishikesh Lokhande, Grace Gombolay, et al.
Multiple Sclerosis and Related Disorders|November 10, 2023
Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosisNegar Molazadeh, Tetsuya Akaishi, Gauruv Bose, et al.
Journal of the Neurological Sciences|January 22, 2011
Accounting for disease modifying therapy in models of clinical progression in multiple sclerosisBrian C Healy, David Engler, Taha Gholipour, et al.
Neurology|August 31, 2016
Pediatric multiple sclerosis: Escalation and emerging treatmentsTanuja Chitnis, Angelo Ghezzi, Barbara Bajer-Kornek, et al.
Journal of the American Society of Nephrology : JASN|March 28, 2003
A novel mechanism for the immunomodulatory functions of class II MHC-derived peptidesBarbara Murphy, Joyce Yu, Qingsheng Jiao, et al.
Pageof 41

Showing results (81-90 of 409) with videos related to

Sort By:
Pageof 41
Neurology|September 30, 2016
Physical activity and the incidence of multiple sclerosisKirsten S Dorans, Jennifer Massa, Tanuja Chitnis, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|February 6, 2023
Fronto-striatal damage may contribute to resistance to fatigue-lowering medications in multiple sclerosisMiklos Palotai, Diana Pintye, Bonnie Glanz, et al.
The Lancet. Neurology|September 27, 2025
Blood and CSF biomarkers for multiple sclerosis: emerging clinical applicationsTanuja Chitnis, Roberta Magliozzi, Ahmed Abdelhak, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2017
Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patientsNeda Sattarnezhad, Samantha Farrow, Dorlan Kimbrough, et al.
Nutritional Neuroscience|March 5, 2021
Triad of hypovitaminosis A, hyperostosis, and optic neuropathy in males with autism spectrum disordersDeena Godfrey, Robert T Stone, Marcus Lee, et al.
Scientific Reports|July 26, 2020
Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseasesShrishti Saxena, Hrishikesh Lokhande, Grace Gombolay, et al.
Multiple Sclerosis and Related Disorders|November 10, 2023
Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosisNegar Molazadeh, Tetsuya Akaishi, Gauruv Bose, et al.
Journal of the Neurological Sciences|January 22, 2011
Accounting for disease modifying therapy in models of clinical progression in multiple sclerosisBrian C Healy, David Engler, Taha Gholipour, et al.
Neurology|August 31, 2016
Pediatric multiple sclerosis: Escalation and emerging treatmentsTanuja Chitnis, Angelo Ghezzi, Barbara Bajer-Kornek, et al.
Journal of the American Society of Nephrology : JASN|March 28, 2003
A novel mechanism for the immunomodulatory functions of class II MHC-derived peptidesBarbara Murphy, Joyce Yu, Qingsheng Jiao, et al.
Pageof 41